Arovella Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapies to treat human disease. The Company focuses on two areas oncology and conditions that impact the central nervous system. The Company’s invariant natural killer T (iNKT) cell therapy platform is to treat blood cancers. It is developing the DKK1 monoclonal antibody (mAb) as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. It is developing anagrelide as an approach to the treatment of cancer, applicable across a range of solid tumors. Anagrelide is used to reduce elevated platelets and lower the thrombotic risk in myeloproliferative diseases associated with high platelet counts. Its ZolpiMist, is an oral spray formulation of zolpidem tartrate to treat short-term insomnia is available in cherry-flavored. The Company is also developing OroMist, an oral spray to treat migraine headaches, motion sickness, and drug-resistant epilepsy.